Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Cancer
- Drug Discovery
- Disease
- Therapeutic
- Assay
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 240618
Licensor hereby grants Licensee an exclusive, worldwide, sublicensable license under the Licensor Intellectual Property to (a) include the Screening Compounds in Licensee’ screening library for use in research conducted by Licensee or its Affiliates (the Screening License) and (b) make, have made, manufacture, have manufactured, formulate, use, have used, sell, offer for sale, have sold, import, export, develop, have developed, register, transport, distribute, promote, market or otherwise dispose or offer to dispose of Non-BCR-ABL Products in the Field in the Territory. For the avoidance of doubt, activities shall be outside the scope of the Collaboration.
Additional Licenses for Research and Development.
(a) Subject to the terms and conditions of this Agreement, Licensor hereby grants to Licensee a non-exclusive, non-sublicensable (except to Affiliates and as permitted) license under the Licensor Background Technology solely to the extent necessary for Licensee to perform its responsibilities under the Research Plan and Development Plan.
(b) Subject to the terms and conditions of this Agreement, Licensee hereby grants to Licensor (i) a non-exclusive, non-sublicensable (except to Affiliates and as permitted) license under the Licensee Intellectual Property solely to the extent necessary for Licensor to perform its responsibilities under the Research Plan and Development Plan; and (ii) a non-exclusive, non-sublicensable (except to Affiliates and as permitted) license under the Licensee Background Technology solely to the extent necessary for Licensor to perform its responsibilities under the Research Plan and Development Plan.
US Application pending #11/192,341 titled Pyrrolo – Pyridine Kinase Modulators
Licensor Patents means the Patent Rights identified and any other Patent Rights Controlled by Licensor or its Affiliates as of the Effective Date or thereafter during the Term having claims covering Collaboration Compounds, Products, Screening Compounds and/or Non-BCR-ABL Products incorporating or comprising a Screening Compound, their use, formulation, preparation or manufacture or having claims which are necessary for research of Collaboration Compounds, Products, Screening Compounds and/or Non-BCR-ABL Products incorporating or comprising a Screening Compound or necessary or useful for the development, manufacture, import, use or sale of Collaboration Compounds, Products, Screening Compounds and/or Non-BCR-ABL Products incorporating or comprising a Screening Compound. For clarification, Licensor Patents includes Licensor’s interest in the Joint Product Patents. For _purposes of this definition, 'Screening Compound' shall include any Compound derived from a Screening Compound if such Compound is within an Licensor Chemotype.
Product means a pharmaceutical product incorporating or comprising a Collaboration Compound in finished dosage form, including in each case, all formulations and modes of administration thereof (by way of example, intravenous, oral, intranasal and transdermal). Product shall not include any Non-BCR-ABL Product.
Licensor Compound means any Compound contained within a Licensor Chemotype.
Licensor Chemotype means (i) a chemotype accepted into the Collaboration and designated by the JRC as a Licensor Chemotype as set forth, and (ii) the chemotypes identified in this agreement, in each case, as any such chemotype may be modified from time to time by the JRC or the JDC, as the case may be.
Licensee Chemotype means a chemotype accepted into the Collaboration and designated by the JRC as a Licensee Chemotype as set forth in this agreement, in each case, as such chemotype may be modified from time to time by the JRC or the JDC, as the case may be.
Compound means a compound and all of its various chemical forms, including acids, bases, salts, isomers, enantiomers, pro-drug forms, hydrates, solvates, polymorphs and degradants thereof in crystal, powder or other form, in existence as of the Effective Date or that arise during the Term.
IPSCIO Record ID: 359061
With respect to the applicable Reversion Compounds being terminated, Licensor grants, effective upon such termination, an exclusive even us to Licensor. sub-licensable, worldwide license under the Licensor Reversion Technology to research, develop, import, use, make. have made, offer for sale and sell Reversion Compounds and Reversion Products including as part of a Licensee Combination Therapy in the Field in the Territory.
Reversion Compound means NLG919, any Next Generation Compound or any Subsequent Compound.
NLG919 means Licensee’s proprietary small molecule IDO inhibitor known as of the Execution Date as NLG919, or any enantiomer, polymorph, salt form, base, acid, racemate, isomer, diastereomer, tautomer, solvate, hydrate, ester or Known Prodrug thereof.
Next Generation Compound means any Compound other than NLG919 that is invented, by or on behalf of Licensee or its Affiliate, whether solely or jointly, as of the Effective Date or thereafter during the Restriction Period, whether or not pursuant to the Research Plan, that is invented or otherwise the subject of research or preclinical development conducted, by or on behalf of Licensor or its Affiliate or Sublicensee, but excluding the pRED Organization, whether solely or jointly, during the Next Gen Research Term, whether or not pursuant to the Research Plan, the composition of matter, manufacture or use of which is Covered by a Valid Claim of a Licensee Patent or Collaboration Patent; or that is an enantiomer, polymorph, salt form, base, acid, racemate, isomer, diastereomer, tautomer, solvate, hydrate, ester or Known Prodrug of a Compound described above.
Indication means any separately defined. well-categorized class of human disease, syndrome or medical condition for which a separate MAA may be filed with a Regulatory Authority. Each different tumor type or a different hematological malignancy as classified by cell lineage (e.g., acute lymphoblastic leukemia is a different Indication from chronic myclogenous leukemia) shall be a separate Indication; however each different line of therapy for a particular tumor type or hematological malignancy will not he considered a separate Indication.
IPSCIO Record ID: 279355
License to Compounds (Other than Collaboration Compounds) Derived from Licensee Compounds – Licensor grants to Licensee a worldwide, exclusive license, with the right to sublicense, under the Licensor IP and Licensors interest in the Collaboration IP, to make, have made, use, sell, offer to sell and import Collaboration Compounds, and/or Collaboration Products based on such Collaboration Compounds, for any and all uses and indications in the Licensee Field.
Collaboration Compound shall mean a Licensor Compound or a Non-Exclusive Compound or a compound that is derived, directly or indirectly, from a Licensee Compound, Licensor Compound, or Non-Exclusive Compound; in each case, that modulates the biological activity of a Collaboration Target at a level of potency to be established by the JRC. A compound shall be deemed to have been derived directly from another compound if it (i) is the result of a chemical modification made to such a compound, (ii) is otherwise obtained from a chemical synthesis program based on one or more such compounds, (iii) is based on proprietary structure-activity data obtained from the testing of one or more such compounds, or (iv) is specifically or generically within the scope of one or more claims of any patent application or patent filed by Licensor or Licensee or their Affiliates to protect any compound in category (i), (ii) or (iii) above. A compound shall be deemed to have been derived indirectly from another compound if it is the result of a series of iterations of any or all of (i) through (iv) above. For purposes of clarity, any compound synthesized in the course of the Collaboration and based on a Licensee Compound, Licensor Compound, or Non-Exclusive Compound which is active against a Collaboration Target at the level of potency established by the JRC shall be deemed a Collaboration Compound. Joint Research Committee or “JRC†shall mean the entity organized to manage the scientific implementation of the Collaboration.
Licensee IP shall mean Licensee Patents and Licensee Know-how.
Collaboration IP shall mean Collaboration Patents and Collaboration Know-how. Collaboration IP shall not include Licensor IP or Licensee IP.
Licensor IP shall mean Licensor Patents and Licensor Know-how. Licensor IP shall not include any intellectual property owned or licensed by Licensor or its Affiliates relating to the ECLiPSâ„¢ technology (i.e., the creation or use of encoded combinatorial libraries or any tag and/or marker compounds).
Licensee Patents shall mean all Patents in the Territory Controlled by Licensee or its Affiliates as the effective date, or any other Patent Controlled by Licensee during the Term; in each case, necessary for the discovery, development, manufacture, importation or use of one or more Collaboration Compounds and/or the development, manufacture, use, sale, importation or commercialization of corresponding Collaboration Products.
Licensor Patents shall mean all Patents in the Territory Controlled by Licensor or its Affiliates as the Effective Date, or any other Patent Controlled by Licensor during the Term; in each case, necessary for the discovery, development, manufacture, importation or use of one or more Collaboration Compounds and/or the development, manufacture, use, sale, importation or commercialization of corresponding Collaboration Products.
Collaboration Patents shall mean (i) all patents and patent applications claiming any invention or discovery which was conceived or reduced to practice during the Collaboration Term and in the course of the Collaboration, by employees or agents of Licensee, Licensor or any of their respective Affiliates, either alone or jointly (including, without limitation, the synthesis and composition of matter of any Collaboration Compound, or method of use thereof; and (ii) any divisions, continuations, continuations-in-part, reissues, reexaminations, extensions or other governmental actions which extend any of the subject matter of the patent applications or patents in (i) above, and any substitutions, confirmations, registrations, revalidations, or additions of any of the foregoing, in each case, which is owned or Controlled, in whole or part, by license, assignment or otherwise by Licensor or Licensee during the term of this Agreement; provided, however, that Collaboration Patents shall not include any Licensee Patents or Licensor Patents.
Licensor Compound shall mean any compound brought to the Collaboration by Licensor, which is Controlled by Licensor at or after the Effective Date, and which is proprietary to Licensor by virtue of being within the Licensor IP.
Licensor Field shall mean, with respect to each Collaboration Compound for which Licensor has received approval to develop pursuant, all human and animal disorders and diseases treated by modulation of a Collaboration Target by such Collaboration Compound.
Licensee Field shall mean, with respect to each Collaboration Compound, all human and animal disorders and diseases treated by modulation of a Collaboration Target by such Collaboration Compound.
IPSCIO Record ID: 222558
For the Collaboration Target-Specific Technology, Licensor grants an exclusive license, exclusive even as to Licensor and its Affiliates, under all of Licensors interest in the Collaboration Target-Specific Technology for any and all purposes in the Territory, including the right to grant sublicenses.
For the Collaboration Platform Technology, upon conclusion of the Collaboration Term, the Parties each grant, to the other a co-exclusive license under their respective interests in the Collaboration Platform Technology in the Territory, as follows the Parties may each use such Collaboration Platform Technology for any and all internal uses, including without limitation, in collaboration with Third Parties for drug discovery.
For the Columbia Sublicense, Licensor grants a non-exclusive sublicense, without the right to sublicense, under the Columbia License, to make, have made, use, offer to sell, sell, import and export Agreement Products in the Territory, including, without limitation, the right to decode Library Compounds.
Product means any Agreement Product or Licensees Product.
Agreement Product shall mean any product containing an Agreement Compound, including, without limitation, products for the therapeutic or prophylactic treatment or prevention of diseases and conditions in human beings or animals.
Licensees Product shall mean any product for the therapeutic or prophylactic treatment or prevention of diseases and conditions in human beings containing a Licensee Compound, provided such Licensee Product is not a Combination Product containing both a Licensee Compound and an Agreement Compound.
Active Compound shall mean a Library Compound that demonstrates activity against a specific Target, which Library Compound was found to have such activity at a concentration set forth in the applicable Collaboration Research Plan during screening of one or more Libraries by Licensor in the conduct of the Collaboration or was found to have such activity during screening by or on behalf of Licensee.
Licensor's combinatorial chemistry technology as an important component in our ongoing efforts to accelerate the drug discovery process and to identify lead compounds for development as new therapeutic entities.'
IPSCIO Record ID: 279359
Product shall mean any pharmaceutical preparation suitable for administration for human use containing the Compound as an active ingredient.
Compound shall mean the chemical compound [N-[3-(4,5-bipyrimidin-2-ylamino)-4-methylphenyl)-4-
{ [ (3S )-3-( dimethylamino) pyrrolidin- 1-yl) methyl}-3-(trifluoromethyl) benzamide], of which code name is designated as __-187.
Chronic myelogenous leukemia (CML) is a cancer that affects your blood cells and bone marrow — the soft part inside your bones where blood cells are made.
IPSCIO Record ID: 280326
License to Commercialize Collaboration Compounds – With respect to all Collaboration Compounds for which Licensee has received Licensors approval to develop and commercialize, Licensor grants to Licensee a worldwide, exclusive license, with the right to sublicense, under the Licensor IP and Licensor’s interest in the Collaboration IP, to make, have made, use, sell, offer to sell and import Collaboration Compounds, and/or Collaboration Products based on such Collaboration Compounds, for any and all uses and indications in the Licensee Field.
License to Compounds (Other than Collaboration Compounds) Derived from Licensee Compounds – Licensor grants to Licensee a worldwide, perpetual, exclusive, royalty-free license, with the right to sublicense, under Licensors interest in the Collaboration IP, to exploit for any and all purposes all compounds (other than Collaboration Compounds) derived, directly or indirectly, from Licensee Compounds.
Research Licenses – The Parties hereby grant each other non-exclusive, worldwide, royalty-free research licenses, without the right to sublicense, under their respective interests in the Licensee IP, Licensor IP and Collaboration IP, in order for each Party to perform its research obligations pursuant to Research Plans during the Collaboration Term.
Licensee IP shall mean Licensee Patents and Licensee Know-how. Licensee IP shall not include any intellectual property owned or licensed by Licensee or its Affiliates relating to the ECLiPSâ„¢ technology (i.e., the creation or use of encoded combinatorial libraries or any tag and/or marker compounds).
Licensor Field shall mean, with respect to each Collaboration Compound, all human and animal disorders and diseases treated by modulation of a Collaboration Target by such Collaboration Compound.
The primary objective of the alliance is to identify active molecules and bring them forward to clinical proof of concept, yielding novel candidates for drug development in various therapeutic areas.
